NASDAQ:SWTX

SpringWorks Therapeutics Competitors

$73.97
+4.56 (+6.57 %)
(As of 04/14/2021 01:21 PM ET)
Add
Compare
Today's Range
$70.40
Now: $73.97
$74.91
50-Day Range
$65.10
MA: $74.27
$93.59
52-Week Range
$26.11
Now: $73.97
$96.48
Volume4,448 shs
Average Volume373,727 shs
Market Capitalization$3.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92

Competitors

SpringWorks Therapeutics (NASDAQ:SWTX) Vs. QGEN, RGEN, CRSP, NBIX, XLRN, and FATE

Should you be buying SWTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to SpringWorks Therapeutics, including QIAGEN (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Acceleron Pharma (XLRN), and Fate Therapeutics (FATE).

QIAGEN (NYSE:QGEN) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Risk & Volatility

QIAGEN has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Valuation & Earnings

This table compares QIAGEN and SpringWorks Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion7.71$-41,460,000.00$1.4336.09
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.84

QIAGEN has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares QIAGEN and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Analyst Ratings

This is a breakdown of current ratings and target prices for QIAGEN and SpringWorks Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN05902.64
SpringWorks Therapeutics00403.00

QIAGEN currently has a consensus price target of $60.76, suggesting a potential upside of 17.73%. SpringWorks Therapeutics has a consensus price target of $95.20, suggesting a potential upside of 28.70%. Given SpringWorks Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SpringWorks Therapeutics is more favorable than QIAGEN.

Summary

QIAGEN beats SpringWorks Therapeutics on 8 of the 13 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Earnings & Valuation

This table compares SpringWorks Therapeutics and Repligen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.84
Repligen$270.24 million42.28$21.41 million$1.07194.97

Repligen has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SpringWorks Therapeutics and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Repligen13.40%6.58%5.00%

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for SpringWorks Therapeutics and Repligen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00403.00
Repligen00503.00

SpringWorks Therapeutics currently has a consensus target price of $95.20, indicating a potential upside of 28.70%. Repligen has a consensus target price of $219.00, indicating a potential upside of 4.98%. Given SpringWorks Therapeutics' higher probable upside, research analysts plainly believe SpringWorks Therapeutics is more favorable than Repligen.

Summary

Repligen beats SpringWorks Therapeutics on 10 of the 12 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Risk & Volatility

SpringWorks Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for SpringWorks Therapeutics and CRISPR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00403.00
CRISPR Therapeutics241202.56

SpringWorks Therapeutics presently has a consensus target price of $95.20, indicating a potential upside of 28.70%. CRISPR Therapeutics has a consensus target price of $158.80, indicating a potential upside of 25.51%. Given SpringWorks Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SpringWorks Therapeutics is more favorable than CRISPR Therapeutics.

Insider and Institutional Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 17.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares SpringWorks Therapeutics and CRISPR Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.84
CRISPR Therapeutics$289.59 million32.91$66.86 million$1.17107.99

CRISPR Therapeutics has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SpringWorks Therapeutics and CRISPR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
CRISPR Therapeutics-273.10%-20.72%-18.35%

Summary

CRISPR Therapeutics beats SpringWorks Therapeutics on 8 of the 13 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Volatility & Risk

Neurocrine Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Insider and Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Neurocrine Biosciences and SpringWorks Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.41$37.01 million$0.39245.51
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.84

Neurocrine Biosciences has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neurocrine Biosciences and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Neurocrine Biosciences and SpringWorks Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences081202.60
SpringWorks Therapeutics00403.00

Neurocrine Biosciences currently has a consensus price target of $128.7222, suggesting a potential upside of 34.60%. SpringWorks Therapeutics has a consensus price target of $95.20, suggesting a potential upside of 28.70%. Given Neurocrine Biosciences' higher possible upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than SpringWorks Therapeutics.

Summary

Neurocrine Biosciences beats SpringWorks Therapeutics on 11 of the 13 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Risk & Volatility

Acceleron Pharma has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Valuation & Earnings

This table compares Acceleron Pharma and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acceleron Pharma$73.99 million101.54$-124,860,000.00($2.38)-52.13
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.84

SpringWorks Therapeutics has lower revenue, but higher earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Acceleron Pharma and SpringWorks Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acceleron Pharma031012.86
SpringWorks Therapeutics00403.00

Acceleron Pharma currently has a consensus target price of $148.2143, indicating a potential upside of 19.45%. SpringWorks Therapeutics has a consensus target price of $95.20, indicating a potential upside of 28.70%. Given SpringWorks Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe SpringWorks Therapeutics is more favorable than Acceleron Pharma.

Insider and Institutional Ownership

79.8% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 2.5% of Acceleron Pharma shares are owned by company insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Acceleron Pharma and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acceleron Pharma-157.84%-31.62%-28.11%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Summary

SpringWorks Therapeutics beats Acceleron Pharma on 9 of the 14 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Volatility & Risk

SpringWorks Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Insider and Institutional Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 21.4% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares SpringWorks Therapeutics and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Fate Therapeutics-810.13%-35.51%-25.40%

Analyst Recommendations

This is a summary of recent recommendations for SpringWorks Therapeutics and Fate Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00403.00
Fate Therapeutics04902.69

SpringWorks Therapeutics currently has a consensus target price of $95.20, suggesting a potential upside of 28.70%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 25.89%. Given SpringWorks Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe SpringWorks Therapeutics is more favorable than Fate Therapeutics.

Valuation and Earnings

This table compares SpringWorks Therapeutics and Fate Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-20.84
Fate Therapeutics$10.68 million765.28$-98,150,000.00($1.44)-60.52

SpringWorks Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

SpringWorks Therapeutics beats Fate Therapeutics on 8 of the 13 factors compared between the two stocks.


SpringWorks Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
QIAGEN logo
QGEN
QIAGEN
1.5$51.61+0.8%$11.86 billion$1.53 billion63.72
Repligen logo
RGEN
Repligen
1.5$208.62+2.0%$11.66 billion$270.24 million254.41Analyst Report
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$126.35+4.3%$9.12 billion$289.59 million-38.76
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.75+2.9%$8.73 billion$788.10 million102.96Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Gap Down
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$124.08+0.7%$7.46 billion$73.99 million-47.91
Fate Therapeutics logo
FATE
Fate Therapeutics
1.6$87.15+9.5%$7.40 billion$10.68 million-47.36
Twist Bioscience logo
TWST
Twist Bioscience
1.2$148.75+5.3%$6.85 billion$90.10 million-39.67Analyst Report
Analyst Revision
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$55.27+2.2%$6.54 billion$26.68 million-25.01
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.42+4.2%$6.37 billion$195.99 million290.13
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$43.95+1.3%$6.04 billion$85.07 million-46.26
Kodiak Sciences logo
KOD
Kodiak Sciences
1.3$121.36+6.9%$5.78 billionN/A-52.31News Coverage
Gap Down
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$45.34+1.0%$5.74 billion$8.09 million-19.21
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.1$79.86+6.3%$4.67 billion$20,000.00-5.68Gap Up
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.43+0.1%$4.66 billion$503.70 million33.08
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.75+2.0%$4.43 billionN/A-16.02Increase in Short Interest
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$33.03+6.7%$4.34 billionN/A-15.51Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.60+1.3%$3.32 billion$125.57 million-43.04Insider Selling
News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$35.44+9.8%$2.89 billionN/A0.00News Coverage
Editas Medicine logo
EDIT
Editas Medicine
1.4$42.17+1.2%$2.81 billion$20.53 million-24.24
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$39.78+5.5%$2.76 billion$50.04 million0.00Insider Selling
Vericel logo
VCEL
Vericel
1.1$57.07+0.8%$2.61 billion$117.85 million-5,707,000.00Increase in Short Interest
Gap Down
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.64+9.3%$1.95 billion$31.43 million-5.23
bluebird bio logo
BLUE
bluebird bio
1.8$29.83+5.0%$1.90 billion$44.67 million-2.72
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.98+5.7%$1.84 billionN/A-11.21Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.1$16.76+4.0%$1.83 billion$40,000.00-23.61Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.42+7.0%$1.72 billion$48.83 million-13.71News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.89+5.1%$1.62 billion$102.43 million-19.82
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$76.09+5.7%$1.59 billionN/A-51.41
AlloVir logo
ALVR
AlloVir
1.4$24.21+2.2%$1.54 billionN/A0.00Increase in Short Interest
Immunovant logo
IMVT
Immunovant
1.8$16.03+3.4%$1.52 billionN/A-12.43Increase in Short Interest
News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.81+3.2%$1.47 billion$35.23 million-14.44Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$31.06+2.3%$1.41 billionN/A-17.55Gap Down
Alector logo
ALEC
Alector
1.3$18.13+3.3%$1.40 billion$21.22 million-8.13
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$35.44+12.3%$1.39 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$33.42+5.5%$1.36 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Translate Bio logo
TBIO
Translate Bio
1.6$18.58+6.2%$1.31 billion$7.80 million-17.36
Ocugen logo
OCGN
Ocugen
1.1$7.04+4.7%$1.26 billionN/A-4.76Increase in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.16+1.8%$1.16 billionN/A-3.06
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$28.52+2.9%$1.14 billion$100.56 million0.00Increase in Short Interest
Gap Down
Mesoblast logo
MESO
Mesoblast
1.4$8.77+1.5%$1.12 billion$32.16 million-9.97Analyst Upgrade
Decrease in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$35.81+0.4%$1.05 billionN/A-14.92Analyst Downgrade
Curis logo
CRIS
Curis
1.1$12.02+5.4%$1.04 billion$10 million-14.66Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.04+0.9%$1.01 billion$356.07 million6.88Unusual Options Activity
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.51+6.1%$988.06 millionN/A0.00Increase in Short Interest
Gap Down
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.53+4.1%$970.33 million$20.49 million-12.25Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.63+0.5%$921.52 millionN/A-4.24Insider Selling
Increase in Short Interest
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.39+3.9%$882.12 million$250,000.00-7.39Analyst Upgrade
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.34+5.9%$878.83 million$42.74 million-226.00Increase in Short Interest
News Coverage
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$25.93+10.3%$878.32 millionN/A0.00Analyst Report
News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.10+2.3%$875.47 million$69.89 million-4.56
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.